General American Investors’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-76,471
| Closed | -$701K | – | 79 |
|
|
2021
Q2 | $701K | Sell |
76,471
-208,529
| -73% | -$1.21M | 0.06% | 71 |
|
|
2021
Q1 | $1.42M | Sell |
285,000
-15,000
| -5% | -$72.4K | 0.13% | 64 |
|
|
2020
Q4 | $1.29M | Sell |
300,000
-216,496
| -42% | -$881K | 0.13% | 65 |
|
|
2020
Q3 | $2.22M | Hold |
516,496
| – | – | 0.26% | 59 |
|
|
2020
Q2 | $2.32M | Hold |
516,496
| – | – | 0.29% | 59 |
|
|
2020
Q1 | $2.07M | Hold |
516,496
| – | – | 0.28% | 54 |
|
|
2019
Q4 | $4.38M | Buy |
516,496
+22,169
| +4% | +$173K | 0.4% | 54 |
|
|
2019
Q3 | $3.39M | Hold |
494,327
| – | – | 0.33% | 55 |
|
|
2019
Q2 | $4.12M | Buy |
494,327
+44,753
| +10% | +$386K | 0.39% | 57 |
|
|
2019
Q1 | $4.12M | Hold |
449,574
| – | – | 0.41% | 57 |
|
|
2018
Q4 | $4.92M | Sell |
449,574
-9,243
| -2% | -$116K | 0.52% | 54 |
|
|
2018
Q3 | $6.4M | Sell |
458,817
-136,061
| -23% | -$1.84M | 0.55% | 55 |
|
|
2018
Q2 | $6.33M | Sell |
594,878
-3,881
| -0.6% | -$37.8K | 0.58% | 54 |
|
|
2018
Q1 | $5.18M | Sell |
598,759
-30,000
| -5% | -$263K | 0.49% | 56 |
|
|
2017
Q4 | $5.94M | Sell |
628,759
-37,708
| -6% | -$295K | 0.58% | 49 |
|
|
2017
Q3 | $5.23M | Buy |
+666,467
| New | +$5M | 0.5% | 54 |
|
Other funds holding KIN
General American Investors's KIN Position: Q3 2021 in Review
General American Investors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 76,471 shares — an estimated $701K sold.
General American Investors first reported a position in KIN in Q3 2017 and held it in 16 quarters. The position peaked at $6.4M in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- General American Investors reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- General American Investors sold 76,471 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $701K.
- General American Investors first reported a position in Kindred Biosciences, Inc. in Q3 2017 and held it in 16 quarters.
- General American Investors's Kindred Biosciences, Inc. position peaked at $6.4M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on General American Investors's 13F filing for Q3 2021, filed 1 Nov 2021.